Kiniksa Pharmaceuticals International, plc
KNSAUS売上高
$678M
百万USD
営業利益
$77M
百万USD
純利益
$59M
百万USD
ROE
10.4%
最新FY
EPS
$0.75
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | - | $-49M | - |
| FY2021 | Q2 | $8M | $-42M | - |
| FY2021 | Q3 | $12M | $-31M | - |
| FY2021 | FY | $39M | $-158M | $-2.30 |
| FY2022 | Q1 | $32M | $-25M | $-0.36 |
| FY2022 | Q2 | $27M | $-20M | $-0.29 |
| FY2022 | Q3 | $99M | $224M | $3.18 |
| FY2022 | FY | $220M | $183M | $2.60 |
| FY2023 | Q1 | $48M | $-12M | $-0.18 |
| FY2023 | Q2 | $71M | $15M | $0.21 |
| FY2023 | Q3 | $67M | $-14M | $-0.20 |
| FY2023 | FY | $270M | $14M | $0.20 |
| FY2024 | Q1 | $80M | $-18M | $-0.25 |
| FY2024 | Q2 | $109M | $-4M | $-0.06 |
| FY2024 | Q3 | $112M | $-13M | $-0.18 |
| FY2024 | FY | $423M | $-43M | $-0.60 |
| FY2025 | Q1 | $138M | $9M | $0.11 |
| FY2025 | Q2 | $157M | $18M | $0.23 |
| FY2025 | Q3 | $181M | $18M | $0.23 |
| FY2025 | FY | $678M | $59M | $0.75 |
| FY2026 | Q1 | $214M | $23M | $0.27 |
財務データ
| 指標 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | - | $39M | $220M | $270M | $423M | $678M |
| 営業利益 | $-108M | $-170M | $-157M | $-157M | $10M | $-25M | $-46M | $77M |
| 純利益 | $-103M | $-162M | $-161M | $-158M | $183M | $14M | $-43M | $59M |
| 総資産 | $322M | $255M | $349M | $233M | $460M | $526M | $581M | $764M |
| 純資産 | - | - | - | - | - | - | - | - |
| 自己資本 | $279M | $225M | $312M | $185M | $396M | $439M | $438M | $568M |
| 営業CF | $-81M | $-158M | $-137M | $-126M | $6M | $13M | $26M | $138M |
| EPS | - | - | - | $-2.30 | $2.60 | $0.20 | $-0.60 | $0.75 |
| BPS | - | - | - | - | - | - | - | - |
| ROE | -37.0% | -71.8% | -51.7% | -85.3% | 46.3% | 3.2% | -9.9% | 10.4% |